Evidence map›Paper›PMID 38295993›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2024

Oral mucosal vaccination using integrated fiber microneedles.

Rachel L Creighton, Kate A Faber, Carmen I Tobos, My-Anh Doan, Teri Guo, Kim A Woodrow

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Assessment ofMolecular pharmaceutics · 2025
    Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rachel L CreightonDepartment of Bioengineering, University of Washington, 3720 15(th) Ave NE, Seattle, WA 98195, USA.
Kate A FaberDepartment of Bioengineering, University of Washington, 3720 15(th) Ave NE, Seattle, WA 98195, USA.
Carmen I TobosDepartment of Bioengineering, University of Washington, 3720 15(th) Ave NE, Seattle, WA 98195, USA.
My-Anh DoanDepartment of Bioengineering, University of Washington, 3720 15(th) Ave NE, Seattle, WA 98195, USA.
Teri GuoDepartment of Bioengineering, University of Washington, 3720 15(th) Ave NE, Seattle, WA 98195, USA.
Kim A WoodrowDepartment of Bioengineering, University of Washington, 3720 15(th) Ave NE, Seattle, WA 98195, USA. Electronic address: woodrow@uw.edu.
University of Washington · US

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Nanomaterials for engineering protection in the genital mucosaDP2HD075703 · NICHD · UNIVERSITY OF WASHINGTON · PI WOODROW, KIM A. · 2012 to 2012
$2.3M
An integrated fiber-microneedle device to study and optimize immune responsesR56DE028539 · NIDCR · UNIVERSITY OF WASHINGTON · PI FULLER, DEBORAH H., WOODROW, KIM A. · 2020 to 2020
$745k
NIAID NIH HHS T32 AI007140NICHD NIH HHS DP2 HD075703NIDCR NIH HHS R56 DE028539
6 · The paper itself

Abstract

The oral mucosa is an attractive site for immunization due to its accessibility and ability to elicit local and systemic immune responses. However, evaluating oral mucosal immunogenicity has proven challenging due to the physical barriers and immunological complexity of the oral mucosa. Microneedles can overcome these physical barriers, but previous work has been limited in the scope of microneedle delivery site, geometry, and release kinetics, all of which are expected to affect physiological responses. Here, we develop integrated fiber microneedle devices, an oral dosage form with tunable geometries and material configurations capable of both burst and sustained release to controlled depths in the oral mucosa. Integrated fiber microneedles administered to either the buccal or sublingual mucosa result in seroconversion and antigen-specific interferon-γ secretion in splenocytes. The dynamics and magnitude of the resulting immune response can be modulated by tuning microneedle release kinetics. Optimal microneedle geometry is site-specific, with longer microneedles eliciting greater immunogenicity in the buccal mucosa, and shorter microneedles eliciting greater immunogenicity in the sublingual mucosa. The Th1/Th2 phenotype of the resulting immune response is also dependent on integrated fiber microneedle length. Together, these results establish integrated fiber microneedles as a multifunctional delivery system for the oral mucosa and motivate further exploration using tunable delivery systems to better understand oral mucosal immunity.

Indexed as

AntigensMouth MucosaAdministration, CutaneousDrug Delivery SystemsImmunity, MucosalNeedlesVaccinationAntigensElectrospun fibersMicroneedleMucosal immunizationOral mucosal deliveryOvalbuminVaccine

Identifiers

PMID38295993
PMCPMC11010722
OpenAlexW4391669329

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.